<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">632476</article-id><article-id pub-id-type="doi">10.26442/00403660.2024.05.202698</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Uric acid, cognitive disorders, neurodegeneration</article-title><trans-title-group xml:lang="ru"><trans-title>Мочевая кислота, когнитивные расстройства, нейродегенерация</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><contrib-id contrib-id-type="scopus">23472651800</contrib-id><contrib-id contrib-id-type="spin">2524-7320</contrib-id><name-alternatives><name xml:lang="en"><surname>Eliseev</surname><given-names>Maxim S.</given-names></name><name xml:lang="ru"><surname>Елисеев</surname><given-names>Максим Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат мед. наук, зав. лаб. микрокристаллических артритов</p></bio><email>elicmax@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5394-7869</contrib-id><contrib-id contrib-id-type="scopus">57196043599</contrib-id><contrib-id contrib-id-type="spin">8038-6195</contrib-id><name-alternatives><name xml:lang="en"><surname>Zheliabina</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Желябина</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>младший научный сотрудник</p></bio><email>olga-sheliabina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1598-8360</contrib-id><contrib-id contrib-id-type="scopus">7102614711</contrib-id><contrib-id contrib-id-type="spin">5162-6484</contrib-id><name-alternatives><name xml:lang="en"><surname>Nasonov</surname><given-names>Evgeny L.</given-names></name><name xml:lang="ru"><surname>Насонов</surname><given-names>Евгений Львович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, доктор мед. наук, проф., науч. рук. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», проф. каф. внутренних, профессиональных болезней и ревматологии</p></bio><email>nasonov@irramn.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. 
Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-06-03" publication-format="electronic"><day>03</day><month>06</month><year>2024</year></pub-date><volume>96</volume><issue>5</issue><issue-title xml:lang="en">Issues of rheumatology</issue-title><issue-title xml:lang="ru">Вопросы ревматологии</issue-title><fpage>447</fpage><lpage>452</lpage><history><date date-type="received" iso-8601-date="2024-05-22"><day>22</day><month>05</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-05-29"><day>29</day><month>05</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/632476">https://ter-arkhiv.ru/0040-3660/article/view/632476</self-uri><abstract xml:lang="en"><p>This article examines the role of uric acid (UA) in cognitive changes and neurodegeneration, focusing on its functions as an antioxidant and prooxidant. Research suggests that changes in serum UA levels may be associated with the development or delay of cognitive impairment, especially in the context of neurodegenerative diseases such as Alzheimer's disease. It was revealed that there is a relationship between the level of UA and the dynamics of cognitive functions, indicating the potential neuroprotective properties of UA. Particular attention is paid to the balance between the antioxidant and prooxidant properties of UA, which may play a key role in protecting neurons from damage. However, research results are not clear-cut, highlighting the need for further research to more fully understand the role of UA in cognitive processes. Determining the optimal serum UA level may be an important step in developing strategies for the prevention and treatment of cognitive impairment associated with neurodegeneration. Overall, these studies advance the understanding of the mechanisms underlying the interaction between uric acid metabolism and brain health.</p></abstract><trans-abstract xml:lang="ru"><p>В данной статье рассматривается роль мочевой кислоты (МК) в когнитивных изменениях и нейродегенерации, акцентируется внимание на ее функциях как антиоксиданта и прооксиданта. Исследования показывают, что изменения уровней МК в сыворотке крови могут быть связаны с развитием или замедлением когнитивных нарушений, особенно в контексте нейродегенеративных заболеваний, таких как болезнь Альцгеймера. Выявлено, что существует взаимосвязь между уровнем МК и динамикой когнитивных функций, указывая на потенциальные нейропротекторные свойства МК. Особое внимание уделяется балансу между антиоксидантными и прооксидантными свойствами МК, который может играть ключевую роль в защите нейронов от повреждения. Однако результаты работ не являются однозначными, подчеркивая необходимость дальнейших исследований для более полного понимания роли МК в когнитивных процессах. Определение оптимального уровня МК в сыворотке может стать важным шагом в разработке стратегий профилактики и лечения когнитивных нарушений, связанных с нейродегенерацией. В целом данные исследования расширяют понимание механизмов, лежащих в основе взаимодействия между метаболизмом МК и здоровьем мозга.</p></trans-abstract><kwd-group xml:lang="en"><kwd>uric acid</kwd><kwd>neurodegeneration</kwd><kwd>cognitive function</kwd><kwd>antioxidant</kwd><kwd>prooxidant</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мочевая кислота</kwd><kwd>нейродегенерация</kwd><kwd>когнитивные функции</kwd><kwd>антиоксидант</kwd><kwd>прооксидант</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was conducted as a part of an applied research project with state registration No. 123041800013-3.</funding-statement><funding-statement xml:lang="ru">Работа выполнена в рамках прикладного научного исследования, государственный регистрационный №123041800013-3</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mijailovic NR, Vesic K, Borovcanin MM. The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction. Front Psychiatr. 2022;13. DOI:10.3389/fpsyt.2022.828476</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wang T, Wu Y, Sun Y, et al. A Prospective Study on the Association between Uric Acid and Cognitive Function among Middle-Aged and Older Chinese. J Alzheimers Dis. 2017;58(1):79-86. DOI:10.3233/JAD-161243</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chen-Xu M, Yokose C, Rai SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991-9. DOI:10.1002/art.40807</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kuwabara M, Fukuuchi T, Aoki Y, et al. Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. Biomolecules. 2023;13(10):1519. DOI:10.3390/biom13101519</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol. 2012;63:1-29. DOI:10.1146/annurev-psych-120710-100422</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zhu Z, Zwerling JL, Qi X, et al. Mechanisms of Change in Cognitive Function Domains Among Older Adults in Cognitive Deterioration and Improvement Groups: Evidence From Phenotypic Network Structure. J Am Med Dir Assoc. 2023;24(12):2009-16.e9. DOI:10.1016/j.jamda.2023.08.022</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Jaeggi SM, Buschkuehl M, Jonides J, et al. Improving fluid intelligence with training on working memory. Proc Natl Acad Sci U S A. 2008;105(19):6829-33. DOI:10.1073/pnas.0801268105</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Guerreiro S, Privat AL, Bressac L, Toulorge D. CD38 in Neurodegeneration and Neuroinflammation. Cells. 2020;9(2):471. DOI:10.3390/cells9020471</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019;322(16):1589-99. DOI:10.1001/jama.2019.4782</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-46. DOI:10.1016/S0140-6736(20)30367-6</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Tang X, Song Z-H, Cardoso MA, et al. The relationship between uric acid and brain health from observational studies. Metab Brain Dis. 2022;37(6):1989-2003. DOI:10.1007/s11011-022-01016-2</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Fumagalli M, Lecca D, Abbracchio MP, Ceruti S. Pathophysiological Role of Purines and Pyrimidines in Neurodevelopment: Unveiling New Pharmacological Approaches to Congenital Brain Diseases. Front Pharmacol. 2017;8:941. DOI:10.3389/fphar.2017.00941</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Orowan E. The origin of man. Nature. 1955;175(4459):683-4. DOI:10.1038/175683a0</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Stetten D Jr, Hearon JZ. Intellectual level measured by army classification battery and serum uric acid concentration. Science. 1959;129(3365):1737. DOI:10.1126/science.129.3365.1737</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Liu Q, Peng M, Yang T, Si G. Uric acid levels and risk of cognitive impairment: Dose-response meta-analysis of prospective cohort studies. PLoS One. 2023;18(11):e0293832. DOI:10.1371/journal.pone.0293832</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Huang S, Wang J, Fan DY, et al. The association of serum uric acid with cognitive impairment and ATN biomarkers. Front Aging Neurosci. 2022;14:943380. DOI:10.3389/fnagi.2022.943380</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Min KH, Kang SO, Oh SJ, et al. Association Between Gout and Dementia in the Elderly: A Nationwide Population-Based Cohort Study. Am J Geriatr Psychiatr. 2021;29(12):1177-85. DOI:10.1016/j.jagp.2021.01.016</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Merighi S, Nigro M, Travagli A, et al. A2A Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity? Int J Mol Sci. 2022;23(9):5056. DOI:10.3390/ijms23095056</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Rheumatology Science and Practice. 2016;54(1):60-77 (in Russian)]. DOI:10.14412/1995-4484-2016-60-77</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Wang J, Jin R, Wu Z, et al. Moderate increase of serum uric acid within a normal range is associated with improved cognitive function in a non-normotensive population: A nationally representative cohort study. Front Aging Neurosci. 2022;14:944341. DOI:10.3389/fnagi.2022.944341</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Liu Q, Liao X, Pan Y, et al. Association Between Serum Uric Acid Levels and Cognitive Function in Patients with Ischemic Stroke and Transient Ischemic Attack (TIA): A 3-Month Follow-Up Study. Neuropsychiatr Dis Treat. 2021;17:991-9. DOI:10.2147/NDT.S300893</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Kawada T. Serum uric acid and dementia subtype. Neurol Sci. 2023;44(8):2951. DOI:10.1007/s10072-023-06798-6</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Johnson RJ, Tolan DR, Bredesen D, et al. Could Alzheimer's disease be a maladaptation of an evolutionary survival pathway mediated by intracerebral fructose and uric acid metabolism? Am J Clin Nutr. 2023;117(3):455-66. DOI:10.1016/j.ajcnut.2023.01.002</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Du N, Xu D, Hou X, et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer's Disease Risk. Mol Neurobiol. 2016;53(4):2594-9. DOI:10.1007/s12035-015-9271-6</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One. 2014;9(4):e94084. DOI:10.1371/journal.pone.0094084</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Cervellati C, Cremonini E, Bosi C, et al. Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res. 2013;10(4):365-72. DOI:10.2174/1567205011310040003</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Beydoun MA, Beydoun HA, Gamaldo AA, et al. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643. DOI:10.1186/1471-2458-14-643</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Seifar F, Dinasarapu AR, Jinnah HA. Uric Acid in Parkinson's Disease: What Is the Connection? Mov Disord. 2022;37(11):2173-83. DOI:10.1002/mds.29209</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Tahavvori A, Gargari MK, Yazdani Y, et al. Involvement of antioxidant enzymes in Parkinson's disease. Pathol Res Pract. 2023;249:154757. DOI:10.1016/j.prp.2023.154757</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain. 2009(Pt. 2): 132:377-82. DOI:10.1093/brain/awn316</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Verhaaren BF, Vernooij MW, Dehghan A, et al. The relation of uric acid to brain atrophy and cognition: The Rotterdam Scan Study. Neuroepidemiology. 2013;41:29-34. DOI:10.1159/000346606</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Hong JY, Lan TY, Tang GJ, et al. Gout and the risk of dementia: A nationwide population-based cohort study. J Arthritis Res Ther. 2015;17:139. DOI:10.1186/s13075-015-0642-1</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Li Q, Cen K, Cui Y, et al. Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis. Neurol Sci. 2023;44(6):2017-24. DOI:10.1007/s10072-023-06620-3</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Kawada T, Anang JB, Postuma R. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology. 2015;84(12):1285. DOI:10.1212/WNL.0000000000001408</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Latourte A, Soumaré A, Bardin T, et al. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 2018;77(3):328-35. DOI:10.1136/annrheumdis-2016-210767</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Scheepers LEJM, Jacobsson LTH, Kern S, et al. Urate and risk of Alzheimer's disease and vascular dementia: A population-based study. Alzheimers Dement. 2019;15(6):754-63. DOI:10.1016/j.jalz.2019.01.014</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Salam AP, Borsini A, Zunszain PA. Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders. Mol Psychiatry. 2018;23(2):170-6. DOI:10.1038/mp.2017.186</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Noz MP, Ter Telgte A, Wiegertjes K, et al. Trained Immunity Characteristics Are Associated With Progressive Cerebral Small Vessel Disease. Stroke. 2018;49(12):2910-7. DOI:10.1161/STROKEAHA.118.023192</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Sfera A, Gradini R, Cummings M, et al. Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease. Front Neurol. 2018;9:1062. DOI:10.3389/fneur.2018.01062</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Cabău G, Crișan TO, Klück V, et al. Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunol Rev. 2020;294(1):92-105. DOI:10.1111/imr.12833</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Tanaka T, Milaneschi Y, Zhang Y, et al. A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: a pilot study. PLoS ONE. 2017;12(8):1-19. DOI:10.1371/journal.pone.0181100</mixed-citation></ref></ref-list></back></article>
